Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Anal Cancer
What would you include in your radiation field for a cT2N1 perianal squamous cell carcinoma in the setting of VIN3, CIN3 and AIN3?
Related Questions
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
Would you offer any adjuvant therapy for a young patient with anal cancer s/p definitive chemoradiation and R0 resection with significant residual disease?
How would you plan adjuvant radiation for an incidental gallbladder carcinoma after cholecystectomy, pT2 with negative margins, now s/p partial hepatectomy and lymphadenectomy with positive nodal disease in a patient who could not tolerate systemic therapy?
In a patient with metastatic colorectal cancer to the lung and liver, is there a role for liver directed therapy if the lung is not amenable to local therapy?
What would be your radiotherapy plan for an overall stage IIA, low-lying, MMRd rectal adenocarcinoma to try to avoid APR?
In a patient with prior RT to the prostate and SVs and newly diagnosed, locally advanced rectal cancer at 10-15 cm, would you offer preoperative chemoradiation?
Is there a role for quad-shot or similar regimen in a patient with a technically resectable, but medically inoperable colon cancer that is both bleeding and causing a partial obstruction?
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
How do you manage oxaliplatin-induced splenomegaly?
If a patient with initially borderline resectable pancreatic cancer receives neoadjuvant CHT followed by CRT and is ultimately deemed unresectable, do you consider an RT boost?
